Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
30 participants
INTERVENTIONAL
2025-09-15
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optokinetic Virtual Reality Stimulation in Unilateral Vestibular Hypofunction
NCT06517446
The Use of Virtual Reality for the Treatment of Visual Vertigo.
NCT03020654
Concurrent Vestibular Activation and Postural Training Using Virtual Reality
NCT05942781
Virtual Reality Compared to Other Forms of Optokinetic Stimulation in the Rehabilitation of Vestibular Syndromes.
NCT03838562
Vestibular Rehabilitation Incorporated With Optokinetic Stimulation in Peripheral Vestibular Dysfunction Patients
NCT05002374
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MS with Central Vestibular Dysfunction
Participants with multiple sclerosis who have central vestibular dysfunction will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention.
Virtual Reality-Based Optokinetic Stimulation (OKS)
A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.
MS without Central Vestibular Dysfunction
Participants with multiple sclerosis without central vestibular dysfunction will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention.
Virtual Reality-Based Optokinetic Stimulation (OKS)
A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.
Healthy Controls
Healthy participants will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention
Virtual Reality-Based Optokinetic Stimulation (OKS)
A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Virtual Reality-Based Optokinetic Stimulation (OKS)
A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a confirmed diagnosis of MS by a neurologist (for MS groups)
* Not have had a relapse in the last 3 months (for MS patients)
* Have an Expanded Disability Status Scale (EDSS) score of ≤ 4 (for MS patients)
* Be a healthy control with no condition preventing participation
Exclusion Criteria
* Be older than 55 years
* Have any cardiovascular, orthopedic, neurological, or other condition preventing assessments
* Have a history of neurological disorders, head trauma, or chronic psychiatric conditions (for healthy controls)
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hacettepe University
OTHER
Avrasya University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Özge Özdemir
M.Sc.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025/102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.